Validation Study to Investigate the Effect of a New Treatment in Patients With Osteoarthritic Pain
NCT ID: NCT03174145
Last Updated: 2019-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
73 participants
INTERVENTIONAL
2017-09-18
2018-08-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active group
Positive behaviour
Information about T4P1010 treatment
T4P1010 administration
Provide treatment to be taken twice a day between Visit 2 and Visit 5 as add-on therapy to patient's regular analgesic treatment
Pharmacogenetic
Blood sample of 10 millilitres maximum
Questionnaires and diary completion
Personality, pain and disease questionnaires completion during the study Diary completion between Visit 1 and Visit 5
Control group
Pharmacogenetic
Blood sample of 10 millilitres maximum
Questionnaires and diary completion
Personality, pain and disease questionnaires completion during the study Diary completion between Visit 1 and Visit 5
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Positive behaviour
Information about T4P1010 treatment
T4P1010 administration
Provide treatment to be taken twice a day between Visit 2 and Visit 5 as add-on therapy to patient's regular analgesic treatment
Pharmacogenetic
Blood sample of 10 millilitres maximum
Questionnaires and diary completion
Personality, pain and disease questionnaires completion during the study Diary completion between Visit 1 and Visit 5
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Osteoarthritis (OA) of knee or hip diagnosed since at least 6 months.
3. Affiliated with national welfare.
4. Reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
5. Have given written informed consent approved by the relevant Ethics Committee governing the study sites.
6. Pain scores reported during the baseline period preceding randomization with a mean APS on the last 14 reported values before Visit 2 between 3.6 and 8.4 inclusive and to have completed at least 2/3 of each pain score in their diary between Visit 1 and Visit 2.
7. Patient with a unilateral or bilateral OA of the knee or hip diagnosed according to the American College of Rheumatology (ACR) criteria based on clinical and radiographic evidence (Altman et al., 1986) (in case of bilateral OA or OA of both knee and hip, the joint to consider should be the most affected one). The clinical diagnosis of OA will be confirmed by the ACR clinical criteria and medical imaging criteria for classification of OA of the knee or hip based upon the following criteria:
1. Knee or hip pain as an average at least half of the time for the last 3 months before screening visit.
2. OA of the knee, at least 1 of the following 3 conditions:
i. age \> 50, ii. morning stiffness \<30 minutes, iii. crepitus on active motion and osteophytes.
OA of the hip, at least 2 of the following 3 conditions:
i. erythrocyte sedimentation rate \< 20mm/hour, ii. femoral and/or acetabular osteophytes, iii. joint space narrowing (superior, axial, and/or medial). c. Kellgren and Lawrence grade \> 1 as assessed by a recent medical imaging of the referred joint to confirm the diagnosis. If no imaging available, a new anterior- posterior view will be obtained and reviewed by Investigator or his/her delegate(s) to verify that the patient meets the disease diagnostic criteria.
Exclusion Criteria
9. Invariable pain scores reported between Visit 1 and Visit 2 (systematically the same minimum score reported all along, the same mean score reported all along and the same maximum score reported all along).
10. Have initiated (or plan to initiate) a program (or modify an existing program in frequency and/or intensity) of physiotherapy or behavioral therapy such as pain self-management, hypnosis, sophrology, meditation program within 2 weeks prior to Visit 1 or during the study.
11. Pregnant, breastfeeding, or willing to be pregnant during the study.
12. Patients with a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere with the patient's participation in the study.
13. Uncontrolled epilepsy.
14. Any current primary psychiatric condition, including depression or personality disorders (such as Axe II of Diagnostic and Statistical Manual of Mental Disorders (DSM-V); personality disorders and mental retardation).
15. Alcohol dependence or regular use of known drugs of abuse (e.g., amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, and phencyclidine).
16. Any other relevant medical disorder/acute disease state/pain condition like fibromyalgia, lumbalgia, generalized OA judged by the Investigator as likely to interfere with the trial or represent a risk for the patient.
17. Any close relationship with the Investigators or the Sponsor (i.e. belonging to immediate family or subordination link).
18. Under legal protection, according to the national law.
19. Having completed or withdrawn from this study or any study investigating T4P1001.
20. Patient currently enrolled in a clinical trial involving use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study, or in an exclusion period according to the national law.
21. Have planned total knee or hip replacement intervention of the referred joint.
22. Reduced mobility due to OA (use of lower extremity assistive devices other than a cane or a knee sleeve such as crutches or walker or a knee brace or a "shoe lift" in relation to OA is not allowed).
23. Use or plan to use systemic corticosteroids 4 weeks prior to Visit 1 or during the study; Intra-muscular corticosteroid injections or Intra-articular injection of steroids into the referred knee/hip within 3 months before Visit 1 or during the study; Intra-articular injection of corticosteroids into any other sites than the referred knee/hip within 4 weeks prior to Visit 1 or during the study (corticosteroids in topical use are allowed).
24. Have used viscosupplementation or intra articular injection of hyaluronic acid in the referred joint within 3 months prior to Visit 1 or plan to use during the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tools4Patient
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alvaro Pereira
Role: STUDY_DIRECTOR
Tools4Patient
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Liège, Médecine de l'appareil locomoteur
Liège, , Belgium
Eurofins Optimed
Gières, , France
Hopital Saint Antoine AP-HP Rhumatologie
Paris, , France
Hopital Cochin AP-HP Evaluation et traitement de la Douleur
Paris, , France
Mac Clinical Research
Cannock, , United Kingdom
Mac Clinical Research
Liverpool, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trial Results published on EU Clinical Trials Register
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T1010-01
Identifier Type: -
Identifier Source: org_study_id